加强药物警戒报告中的撤药反应以支持减药
Strengthening Pharmacovigilance Reporting for Withdrawal Reactions to Support Deprescribing.
PubMed 文献 · Clin Pharmacol Ther · 2026-06-06
本文讨论药物警戒在上市后监测中依赖自发报告不良反应(ADR),但撤药反应这一ADR亚型未被现行药物警戒实践充分涵盖;作者提出修订现行ADR报告表的建议,以增强对撤药反应证据的捕获。
要点
- 撤药反应是临床相关ADR亚型,现行药物警戒报告表未充分涵盖。
- 建议修订ADR报告表以更好捕获撤药反应证据以支持减药。
- 药物警戒依赖自发报告,撤药反应报告不足影响减药决策证据。
核心结论
- 现行药物警戒实践未充分涵盖撤药反应这一ADR亚型,需修订ADR报告表以增强证据捕获。
主要发现
- 停药可引起临床相关体征和症状,包括撤药反应,但该ADR亚型未被现行药物警戒实践充分容纳。
临床怎么用
- 临床药师在减药过程中应关注并报告撤药反应,利用修订后的ADR报告表提高证据完整性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pharmacovigilance plays a crucial role in post-marketing surveillance of medicines and relies on the spontaneous reporting of adverse drug reactions (ADRs). Discontinuation of a drug can cause clinically relevant signs and symptoms, including withdrawal reactions; however, this subset of ADRs is not fully accommodated in current pharmacovigilance practice. We discuss proposed revisions to current ADR forms that could enhance the capture of withdrawal reaction evidence.
来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。
引用
- Khan Z, Moriarty F. Strengthening Pharmacovigilance Reporting for Withdrawal Reactions to Support Deprescribing. Clin Pharmacol Ther. 2026. PMID: 42249887. doi:10.1002/cpt.70356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。